SG11201702625PA - Boronic acid derivatives - Google Patents

Boronic acid derivatives

Info

Publication number
SG11201702625PA
SG11201702625PA SG11201702625PA SG11201702625PA SG11201702625PA SG 11201702625P A SG11201702625P A SG 11201702625PA SG 11201702625P A SG11201702625P A SG 11201702625PA SG 11201702625P A SG11201702625P A SG 11201702625PA SG 11201702625P A SG11201702625P A SG 11201702625PA
Authority
SG
Singapore
Prior art keywords
acid derivatives
boronic acid
boronic
derivatives
acid
Prior art date
Application number
SG11201702625PA
Other languages
English (en)
Inventor
Markus Klein
Oliver Schadt
Philipp Haselmayer
Michael Busch
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201702625PA publication Critical patent/SG11201702625PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201702625PA 2014-10-01 2015-10-01 Boronic acid derivatives SG11201702625PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14003390 2014-10-01
PCT/EP2015/001930 WO2016050355A1 (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Publications (1)

Publication Number Publication Date
SG11201702625PA true SG11201702625PA (en) 2017-04-27

Family

ID=51690787

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702625PA SG11201702625PA (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Country Status (14)

Country Link
US (1) US10640520B2 (ja)
EP (1) EP3201205B1 (ja)
JP (1) JP6835710B2 (ja)
KR (1) KR20170066506A (ja)
CN (1) CN107108660B (ja)
AU (1) AU2015327411B2 (ja)
BR (1) BR112017006368A2 (ja)
CA (1) CA2963186A1 (ja)
ES (1) ES2811273T3 (ja)
IL (1) IL251300A0 (ja)
MX (1) MX2017004037A (ja)
RU (1) RU2017115193A (ja)
SG (1) SG11201702625PA (ja)
WO (1) WO2016050355A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015327346B2 (en) 2014-10-01 2019-12-05 Merck Patent Gmbh Boronic acid derivatives
MX2017004043A (es) 2014-10-01 2017-07-04 Merck Patent Gmbh Derivados de acido boronico.
BR112017006622A2 (pt) 2014-10-01 2018-07-03 Merck Patent Gmbh derivados de ácido borônico
CN117338932A (zh) * 2017-08-23 2024-01-05 科智生命科学公司 自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
PL3672977T3 (pl) 2017-08-24 2022-09-26 Merck Patent Gmbh Pochodne kwasu boronowego
US20210317145A1 (en) 2018-07-26 2021-10-14 Merck Patent Gmbh Boronic Acid Derivatives
US20220040192A1 (en) * 2018-10-04 2022-02-10 Kezar Life Sciences Immunoproteasome inhibitor formulations
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN114075227B (zh) * 2020-08-19 2023-07-04 北京嵩润医药科技有限责任公司 吡唑硼酸类化合物、包含其的药物组合物及它们的用途
WO2023006863A1 (en) 2021-07-29 2023-02-02 Merck Patent Gmbh Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563127A (en) * 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US6060462A (en) * 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
FR2758329B1 (fr) * 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AU2008321443A1 (en) * 2007-11-13 2009-05-22 Novartis Ag Beta-lactamase inhibitors
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
CA2860142C (en) * 2011-12-22 2020-10-27 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
US9944658B2 (en) * 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2015327346B2 (en) 2014-10-01 2019-12-05 Merck Patent Gmbh Boronic acid derivatives
MX2017004043A (es) 2014-10-01 2017-07-04 Merck Patent Gmbh Derivados de acido boronico.
BR112017006622A2 (pt) 2014-10-01 2018-07-03 Merck Patent Gmbh derivados de ácido borônico

Also Published As

Publication number Publication date
AU2015327411A1 (en) 2017-05-18
AU2015327411B2 (en) 2020-01-02
CN107108660A (zh) 2017-08-29
CA2963186A1 (en) 2016-04-07
US10640520B2 (en) 2020-05-05
JP6835710B2 (ja) 2021-02-24
ES2811273T3 (es) 2021-03-11
EP3201205B1 (en) 2020-05-13
JP2018502049A (ja) 2018-01-25
MX2017004037A (es) 2017-07-04
CN107108660B (zh) 2020-09-15
RU2017115193A3 (ja) 2019-02-08
WO2016050355A1 (en) 2016-04-07
KR20170066506A (ko) 2017-06-14
US20180179231A1 (en) 2018-06-28
BR112017006368A2 (pt) 2017-12-19
RU2017115193A (ru) 2018-11-06
IL251300A0 (en) 2017-05-29
EP3201205A1 (en) 2017-08-09

Similar Documents

Publication Publication Date Title
ZA201703007B (en) Boronic acid derivatives
GB201419865D0 (en) Solution
GB201517022D0 (en) No details
SG11201702620SA (en) Boronic acid derivatives
GB201410907D0 (en) No details
SG11201702625PA (en) Boronic acid derivatives
GB201517404D0 (en) No details
SG11201702623TA (en) Boronic acid derivatives
GB201418217D0 (en) No details
GB201418216D0 (en) No details
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PT3131898T (pt) Derivados de fluoroalquilfluoreno
GB201517412D0 (en) No details
PL3164393T3 (pl) Pochodne flawaglin
GB201516796D0 (en) No details
IL248773A0 (en) History of naphthyridinedione
IL248629A0 (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
PT3672977T (pt) Derivados do ácido borónico
GB201517574D0 (en) No details
DK3200779T3 (en) Novel anthranilic acid derivatives
PT3097076T (pt) Novos derivados cyp-eicosanoides
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
GB201410910D0 (en) No details
GB201417986D0 (en) No details
GB201407585D0 (en) SMA-Inter Act